- Home
- COEP vs CGTX Comparison
COEP vs CGTX Comparison
Compare COEP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- CGTX
- Stock Information
- Founded
- COEP 2017
- CGTX 2007
- Country
- COEP United States
- CGTX United States
- Employees
- COEP N/A
- CGTX N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- CGTX Health Care
- Exchange
- COEP Nasdaq
- CGTX Nasdaq
- Market Cap
- COEP 32.4M
- CGTX 17.2M
- IPO Year
- COEP N/A
- CGTX 2021
- Fundamental
- Price
- COEP $11.06
- CGTX $0.45
- Analyst Decision
- COEP
- CGTX Strong Buy
- Analyst Count
- COEP 0
- CGTX 6
- Target Price
- COEP N/A
- CGTX $8.30
- AVG Volume (30 Days)
- COEP 58.6K
- CGTX 2.9M
- Earning Date
- COEP 05-09-2025
- CGTX 05-06-2025
- Dividend Yield
- COEP N/A
- CGTX N/A
- EPS Growth
- COEP N/A
- CGTX N/A
- EPS
- COEP N/A
- CGTX N/A
- Revenue
- COEP N/A
- CGTX N/A
- Revenue This Year
- COEP N/A
- CGTX N/A
- Revenue Next Year
- COEP N/A
- CGTX N/A
- P/E Ratio
- COEP N/A
- CGTX N/A
- Revenue Growth
- COEP N/A
- CGTX N/A
- 52 Week Low
- COEP $2.31
- CGTX $0.34
- 52 Week High
- COEP $13.70
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- COEP 52.45
- CGTX 37.57
- Support Level
- COEP $10.30
- CGTX $0.39
- Resistance Level
- COEP $11.75
- CGTX $0.46
- Average True Range (ATR)
- COEP 1.02
- CGTX 0.05
- MACD
- COEP -0.08
- CGTX 0.00
- Stochastic Oscillator
- COEP 71.79
- CGTX 34.27
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.